1. Current challenges of metastatic breast cancer
    Bora Lim et al, 2016, Cancer Metastasis Rev CrossRef
  2. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
    Ana C. Gregório et al, 2017, Pathol. Oncol. Res. CrossRef
  3. Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer
    JUN LIU et al, 2015 CrossRef
  4. Repurposing itraconazole for the treatment of cancer
    Rachel Pounds et al, 2017 CrossRef
  5. Effect of antitumor treatments on triple-negative breast cancer patients
    Qiuhong Tian et al, 2017, Medicine CrossRef
  6. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
    Zhipeng Wang et al, 2018, Saudi Journal of Biological Sciences CrossRef
  7. Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
    Patrizia Mancini et al, 2014, Cancers CrossRef
  8. Irinotecan and Capecitabine Combination Chemotherapy in a Patient with Triple-negative Breast Cancer Relapsed after Adjuvant Chemotherapy with Anthracycline and Taxane
    Anna Lee et al, 2015, Tumori Journal CrossRef
  9. Mammakarzinom: Was bringt die S3-Leitlinienaktualisierung Neues?
    Achim Wöckel et al, 2018, Gynäkologe CrossRef
  10. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
    Elizabeth Miller et al, 2014, F1000Res CrossRef
  11. Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
    Emanuel Nicolas et al, 2018, Cancers CrossRef
  12. How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment.
    Diana P Saraiva et al, 2017, ESMO Open CrossRef
  13. S3-Leitlinie „Interdisziplinäre Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms“
    Achim Wöckel et al, 2019, Forum CrossRef
  14. Tripelnegatives Mammakarzinom
    N. Harbeck et al, 2014, best practice onkologie CrossRef
  15. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis
    Fausto Petrelli et al, 2014, Breast Cancer Res Treat CrossRef
  16. Molecular Biology in the Breast Clinics—Current status and future perspectives
    Vani Parmar et al, 2019, Indian J Surg Oncol CrossRef
  17. Obesity and Resistance to Cancer Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation
    L M Lashinger et al, 2014, Clin Pharmacol Ther CrossRef
  18. Past, present, and future challenges in breast cancer treatment.
    George W Sledge et al, 2014, J Clin Oncol CrossRef
  19. Evolution of Pre-Existing versus Acquired Resistance to Platinum Drugs and PARP Inhibitors in BRCA-Associated Cancers
    Kimiyo N. Yamamoto et al, 2014, PLoS ONE CrossRef
  20. ERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapy
    Grazia Palomba et al, 2014, J Transl Med CrossRef
  21. BRCAness Predicts Resistance to Taxane-Containing Regimens in Triple Negative Breast Cancer During Neoadjuvant Chemotherapy
    Sadako Akashi-Tanaka et al, 2015, Clinical Breast Cancer CrossRef
  22. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
    Steven J. Isakoff et al, 2015, JCO CrossRef
  23. Platinum-based chemotherapy in triple-negative breast cancer
    Xiuwen Guan et al, 2015, Anti-Cancer Drugs CrossRef
  24. Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin
    Hideaki Ogata et al, 2015, Medicine CrossRef
  25. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Sara Hurvitz et al, 0 CrossRef
  26. Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response
    Gamal M Elnemr et al, 2016, Asian Pacific Journal of Cancer Prevention CrossRef
  27. Recent Progress in Triple Negative Breast Cancer Research
    Fatima Zahra Mouh et al, 2016, Asian Pacific Journal of Cancer Prevention CrossRef
  28. GPRC5A exerts its tumor-suppressive effects in breast cancer cells by inhibiting EGFR and its downstream pathway
    Lu Yang et al, 2016 CrossRef
  29. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs
    Matthew A. Sanders et al, 2017, J. Biol. Chem. CrossRef
  30. Triple negative breast cancer in Asia: An insider’s view
    Chao Wang et al, 2018, Cancer Treatment Reviews CrossRef
  31. Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
    Johnathan Watkins et al, 2015, Cancer Discovery CrossRef
  32. Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: a systematic review
    Pablo Mandó et al, 2021, Cancer Treatment and Research Communications CrossRef
  33. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
    Zhiying Shao et al, 2016, oncol res CrossRef
  34. null
    Amir Khan et al, 2022 CrossRef
  35. Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses
    Jianyun Yin et al, 2022, IJGM CrossRef
  36. The fate of chemoresistance in triple negative breast cancer (TNBC)
    Elma A. O’Reilly et al, 2015, BBA Clinical CrossRef
  37. Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy
    Liliana-Roxana Balahura (Stămat) et al, 2023, IJMS CrossRef
  38. In vitro models of breast cancer bone metastasis: analyzing drug resistance through the lens of the microenvironment
    Anaïs Lamouline et al, 2023, Front. Oncol. CrossRef
  39. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
    Martina Catalano et al, 2024, Cancer Chemother Pharmacol CrossRef